Susana Roselló

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, F. Ciardiello, 2015, British Journal of Cancer.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

F. J. Ramos, J. Baselga, J. Tabernero, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer.

S. Navarro, A. Cervantes, S. Campos, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

A. Cervantes, K. Jordan, S. Roselló, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness

A. Riffo-Campos, A. Cervantes, L. Franco, 2020, Scientific Reports.

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial

I. Chirivella, A. Bosch, A. Cervantes, 2008, British Journal of Cancer.